These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38698025)

  • 1. Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis.
    Pernice HF; Knorz AL; Wetzel PJ; Herrmann C; Muratovic H; Rieber F; Asaad E; Fiß G; Barzen G; Blüthner E; Knebel F; Spethmann S; Messroghli D; Heidecker B; Brand A; Wetz C; Tschöpe C; Hahn K
    Sci Rep; 2024 May; 14(1):10111. PubMed ID: 38698025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
    Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
    Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral nerve involvement in wild-type transthyretin amyloidosis.
    Campagnolo M; Cacciavillani M; Cipriani A; Salvalaggio A; Castellani F; Pilichou K; Briani C
    Neurol Sci; 2023 Jan; 44(1):351-354. PubMed ID: 36260260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
    Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
    Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
    Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis.
    Annabi MS; Carter-Storch R; Zaroui A; Galat A; Oghina S; Kharoubi M; Bezard M; Derumeaux G; Fanen P; Lemonnier F; Poullot E; Itti E; Gallet R; Teiger E; Pibarot P; Damy T; Clavel MA
    J Am Heart Assoc; 2024 Jul; 13(13):e034723. PubMed ID: 38904242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
    Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
    Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis.
    Wajnsztajn Yungher F; Kim A; Boehme A; Kleyman I; Weimer LH; Maurer MS; Brannagan TH
    J Peripher Nerv Syst; 2020 Sep; 25(3):265-272. PubMed ID: 32627282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Barroso FA; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Wixner J; Maurer MS; Rapezzi C; Planté-Bordeneuve V; Kristen AV; González-Duarte A; Chapman D; Stewart M; Amass L;
    Amyloid; 2022 Sep; 29(3):175-183. PubMed ID: 35451899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis.
    Chan GG; Koch CM; Connors LH
    J Proteome Res; 2017 Apr; 16(4):1659-1668. PubMed ID: 28196416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
    Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
    Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis.
    Kapoor M; Foiani M; Heslegrave A; Zetterberg H; Lunn MP; Malaspina A; Gillmore JD; Rossor AM; Reilly MM
    J Peripher Nerv Syst; 2019 Dec; 24(4):314-319. PubMed ID: 31583784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.
    Živković SA; Lacomis D; Soman P
    Front Cardiovasc Med; 2024; 11():1345608. PubMed ID: 38410247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
    Galosi E; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Lauletta A; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Esposito N; Falco P; di Pietro G; Truini A; Leonardi L
    Neurol Sci; 2024 Oct; 45(10):5023-5032. PubMed ID: 38700599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).
    Sikora JL; Logue MW; Chan GG; Spencer BH; Prokaeva TB; Baldwin CT; Seldin DC; Connors LH
    Hum Genet; 2015 Jan; 134(1):111-21. PubMed ID: 25367359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
    Yunis A; Doros G; Luptak I; Connors LH; Sam F
    Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
    Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
    JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
    Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
    Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.